The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 1, 2002, Pages 136-143

  Singh, Atam B ^a   Hsia, Stanley ^b   Alaupovic, Petar ^c   Sinha Hikim, Indrani ^d   Woodhouse, Linda ^b   Buchanan, Thomas A ^b   Shen, Ruoquing ^a   Bross, Rachelle ^a   Berman, Nancy ^c   Bhasin, Shalender ^a,e  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; GLUCOSE; GONADORELIN AGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TESTOSTERONE ENANTATE; TRIPTORELIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CALORIC INTAKE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; HORMONAL THERAPY; HORMONE ACTION; HUMAN; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID BLOOD LEVEL; MALE; MUSCLE STRENGTH; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE;

EID: 18244390514     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.1.8172     Document Type: Article

References (54)

1. Testosterone supplementation in older men: A rational idea whose time has not yet come
2. Issues in testosterone replacement in older men
3. Effects of testosterone supplementation in the aging male
4. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial
5. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age
6. Effect of testosterone treatment on bone mineral density in men over 65 years of age
7. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels
8. Effects of testosterone replacement in hypogonadal men
9. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism
10. Testosterone deficiency in young men: Marked alterations in whole body protein kinetics, strength, and adiposity
11. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men
12. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men
13. Sexual function does not change when serum testosterone levels are pharmacologically varied within normal male range
14. Testosterone dose-dependency of sexual and non-sexual behaviors in the GnRH-antagonist treated male rat
15. Dissociating antifertility effects of GnRH-antagonist from its adverse effects on mating behavior in male rats
16. Testosterone dose-response relationships in healthy, young men
17. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men
18. Effect of testosterone on abdominal adipose tissue in men
19. Androgen treatment of middle-aged, obese men: Effects on metabolism, muscle and adipose tissues
20. The effects of testosterone on insulin sensitivity in male rats
21. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids
22. The influence of androgens on insulin resistance
23. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
24. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high-density lipoprotein cholesterol
25. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
26. Use and significance of reference serum as a secondary standard for elecrtoimmunoassay of apolipoprotein A-I
27. Electroimmunoassay, radioimmunoassay, and radial immunodiffusion assay evaluated for quantification of human apolipoprotein B
28. Quantitative determination of human apolipoprotein C-III by electroimmunoassay
29. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
30. The use of sensitive, equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women, and HIV-infected women
31. Physiologic evaluation of factors controlling glucose tolerance in man
32. Toward physiologic understanding of glucose tolerance
33. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels
34. High-density-lipoprotein cholesterol in body-builders v powerlifters. Negative effects of androgen use
35. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans
36. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis
37. Relation between plasma high-density lipoprotein cholesterol and sex hormone concentrations in men
38. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study
39. Insulin resistance, body fat distribution, and sex hormones in men
40. Endogenous sex hormones and cardiovascular disease in men
41. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study
42. Sex hormones, insulin, lipids, and prevalent ischemic heart disease
43. The relationship of sex hormones to hyperinsulinemia and hyperglycemia
44. Relationship between sex hormones and glucose-insulin-lipid defect in men with obesity
45. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels
46. The administration of pharmacologic doses of testosterone or 19 norteststerone to normal men is not associated with increase insulin secretion or impaired glucose tolerance
47. Androgen treatment of abdominally obese men
48. Lower endogenous androgens predict central adiposity in men
49. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: Effects of androgens
50. Relationships of generalized and regional adiposity to insulin sensitivity in men
51. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris
52. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice
53. C-reactive protein in rat: In development, pregnancy and effect of sex hormones